FDA clears AZ’s new PNH therapy Voydeya

AstraZeneca’s Voydeya has become the first oral Factor D inhibitor Voydeya to be approved by the FDA as a treatment for the rare disease paroxysmal nocturnal haemoglobinuria (PNH).